PRESS RELEASE 2023

Ferring and PharmaBiome enter into a new microbiome R&D collaboration and exclusive licensing agreement

Ferring and PharmaBiome enter into a new microbiome R&D collaboration and exclusive…

New data show durable response following treatment with ADSTILADRIN® (nadofaragene firadenovec-vncg)

…

Ferring Named in Fortune’s 2023 Change the World List

Royalty Pharma and Ferring Pharmaceuticals enter into US $500 million royalty agreement for new intravesical gene therapy Adstiladrin® (nadofaragene firadenovec-vncg)

Ferring Pharmaceuticals appoints new Executive Chairman among key changes to Board of Directors

Ad hoc announcement pursuant to Art. 53 LR Ferring Pharmaceuticals appoints new…

Four Analyses of Data for REBYOTA™ (fecal microbiota, live – jslm), the First FDA-Approved Microbiome-Based Treatment for the Prevention of Recurrent C. difficile Infection, Presented at DDW 2023

Four Analyses of Data for REBYOTA™ (fecal microbiota, live – jslm), the…

Ferring and BioInnovation Institute enter new strategic collaboration to accelerate innovation in women’s health

Ferring and BioInnovation Institute enter new strategic collaboration to accelerate innovation in…

Ferring announces abstract of the first prospective, multi-national, real-world study of Rekovelle® (follitropin delta) at the congress of the Pacific Society for Reproductive Medicine

Ferring announces abstract of the first prospective, multi-national, real-world study of Rekovelle®…

Approval of new medicines in 2022 sets Ferring on course for future growth and diversification

Approval of new medicines in 2022 sets Ferring on course for future…

Ferring Pharmaceuticals appoints Pierre-Yves Berclaz as Executive Vice President, Chief Medical Officer

Ferring Pharmaceuticals appoints Pierre-Yves Berclaz as Executive Vice President, Chief Medical Officer…